Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer
Background: Peroxisomes are central metabolic organelles that have key roles in fatty acid homoeostasis. As prostate cancer (PCa) is particularly reliant on fatty acid metabolism, we explored the contribution of peroxisomal β-oxidation (perFAO) to PCa viability and therapy response. Methods: Bioinfo...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer Nature [academic journals on nature.com]
2024
|
| _version_ | 1811139382182150144 |
|---|---|
| author | Mah, CY Nguyen, ADT Niijima, T Helm, M Dehairs, J Ryan, FJ Ryan, N Quek, L Hoy, AJ Don, AS Mills, IG Swinnen, JV Lynn, DJ Nassar, ZD Butler, LM |
| author_facet | Mah, CY Nguyen, ADT Niijima, T Helm, M Dehairs, J Ryan, FJ Ryan, N Quek, L Hoy, AJ Don, AS Mills, IG Swinnen, JV Lynn, DJ Nassar, ZD Butler, LM |
| author_sort | Mah, CY |
| collection | OXFORD |
| description | Background: Peroxisomes are central metabolic organelles that have key roles in fatty acid homoeostasis. As prostate cancer (PCa) is particularly reliant on fatty acid metabolism, we explored the contribution of peroxisomal β-oxidation (perFAO) to PCa viability and therapy response. Methods: Bioinformatic analysis was performed on clinical transcriptomic datasets to identify the perFAO enzyme, 2,4-dienoyl CoA reductase 2 (DECR2) as a target gene of interest. Impact of DECR2 and perFAO inhibition via thioridazine was examined in vitro, in vivo, and in clinical prostate tumours cultured ex vivo. Transcriptomic and lipidomic profiling was used to determine the functional consequences of DECR2 inhibition in PCa. Results: DECR2 is upregulated in clinical PCa, most notably in metastatic castrate-resistant PCa (CRPC). Depletion of DECR2 significantly suppressed proliferation, migration, and 3D growth of a range of CRPC and therapy-resistant PCa cell lines, and inhibited LNCaP tumour growth and proliferation in vivo. DECR2 influences cell cycle progression and lipid metabolism to support tumour cell proliferation. Further, co-targeting of perFAO and standard-of-care androgen receptor inhibition enhanced suppression of PCa cell proliferation. Conclusion: Our findings support a focus on perFAO, specifically DECR2, as a promising therapeutic target for CRPC and as a novel strategy to overcome lethal treatment resistance. |
| first_indexed | 2024-09-25T04:05:12Z |
| format | Journal article |
| id | oxford-uuid:6bb296c4-3601-4edb-ac0d-fac485f8befe |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:05:12Z |
| publishDate | 2024 |
| publisher | Springer Nature [academic journals on nature.com] |
| record_format | dspace |
| spelling | oxford-uuid:6bb296c4-3601-4edb-ac0d-fac485f8befe2024-05-30T09:50:01ZPeroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6bb296c4-3601-4edb-ac0d-fac485f8befeEnglishJisc Publications RouterSpringer Nature [academic journals on nature.com]2024Mah, CYNguyen, ADTNiijima, THelm, MDehairs, JRyan, FJRyan, NQuek, LHoy, AJDon, ASMills, IGSwinnen, JVLynn, DJNassar, ZDButler, LMBackground: Peroxisomes are central metabolic organelles that have key roles in fatty acid homoeostasis. As prostate cancer (PCa) is particularly reliant on fatty acid metabolism, we explored the contribution of peroxisomal β-oxidation (perFAO) to PCa viability and therapy response. Methods: Bioinformatic analysis was performed on clinical transcriptomic datasets to identify the perFAO enzyme, 2,4-dienoyl CoA reductase 2 (DECR2) as a target gene of interest. Impact of DECR2 and perFAO inhibition via thioridazine was examined in vitro, in vivo, and in clinical prostate tumours cultured ex vivo. Transcriptomic and lipidomic profiling was used to determine the functional consequences of DECR2 inhibition in PCa. Results: DECR2 is upregulated in clinical PCa, most notably in metastatic castrate-resistant PCa (CRPC). Depletion of DECR2 significantly suppressed proliferation, migration, and 3D growth of a range of CRPC and therapy-resistant PCa cell lines, and inhibited LNCaP tumour growth and proliferation in vivo. DECR2 influences cell cycle progression and lipid metabolism to support tumour cell proliferation. Further, co-targeting of perFAO and standard-of-care androgen receptor inhibition enhanced suppression of PCa cell proliferation. Conclusion: Our findings support a focus on perFAO, specifically DECR2, as a promising therapeutic target for CRPC and as a novel strategy to overcome lethal treatment resistance. |
| spellingShingle | Mah, CY Nguyen, ADT Niijima, T Helm, M Dehairs, J Ryan, FJ Ryan, N Quek, L Hoy, AJ Don, AS Mills, IG Swinnen, JV Lynn, DJ Nassar, ZD Butler, LM Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer |
| title | Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer |
| title_full | Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer |
| title_fullStr | Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer |
| title_full_unstemmed | Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer |
| title_short | Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer |
| title_sort | peroxisomal β oxidation enzyme decr2 regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer |
| work_keys_str_mv | AT mahcy peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer AT nguyenadt peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer AT niijimat peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer AT helmm peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer AT dehairsj peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer AT ryanfj peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer AT ryann peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer AT quekl peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer AT hoyaj peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer AT donas peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer AT millsig peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer AT swinnenjv peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer AT lynndj peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer AT nassarzd peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer AT butlerlm peroxisomalboxidationenzymedecr2regulateslipidmetabolismandpromotestreatmentresistanceinadvancedprostatecancer |